- ProBioGen has entered into a collaboration with VarmX B.V. to develop VarmX’s second therapeutic Factor X candidate using ProBioGen’s proprietary HEK293 host cell line platform.
- The partnership will focus on cell line development and builds on ProBioGen’s experience in developing coagulation factor therapeutics, including Factor VII and Factor VIII programs.
ProBioGen has announced a collaboration with VarmX B.V. to support the development of VarmX’s second therapeutic Factor X candidate. Under the agreement, ProBioGen will provide cell line development using its proprietary HEK293 host cell line platform to advance the coagulation factor program.
The collaboration builds on ProBioGen’s experience in coagulation factor development, including previous work on Factor VII and Factor VIII therapeutics. According to the company, its HEK293 platform, combined with its DirectedLuck® transposase technology, is designed to address development challenges associated with coagulation factors by supporting protein maturation, proteolytic processing, and biologic activity.
“We are excited to partner with VarmX on this compelling and demanding molecule. Combined with the DirectedLuck® transposase technology, our HEK293 platform is ideally suited to address the unique development challenges associated with coagulation factors.”
Dr. Volker Sandig, Chief Scientific Officer of ProBioGen
VarmX said it selected ProBioGen based on the company’s experience in coagulation factor development and its HEK293 technology. According to the companies, the collaboration is intended to support the advancement of VarmX’s second therapeutic Factor X candidate through the next stage of development.
